This article was downloaded by: [Michigan State University] On: 23 February 2015, At: 00:12 Publisher: Taylor & Francis Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK
Human Vaccines & Immunotherapeutics Publication details, including instructions for authors and subscription information: http://www.tandfonline.com/loi/khvi20
Letter from the Editor a
Ronald Ellis & Eva M Riedmann a
b
Senior Vice President R&D and Chief Technology Officer; NasVax, Ltd.; Ness Ziona, Israel
b
Acquisitions Editor; Landes Bioscience; Vienna, Austria Published online: 05 Nov 2013.
To cite this article: Ronald Ellis & Eva M Riedmann (2013) Letter from the Editor, Human Vaccines & Immunotherapeutics, 9:11, 2277-2278, DOI: 10.4161/hv.27083 To link to this article: http://dx.doi.org/10.4161/hv.27083
PLEASE SCROLL DOWN FOR ARTICLE Taylor & Francis makes every effort to ensure the accuracy of all the information (the “Content”) contained in the publications on our platform. Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Versions of published Taylor & Francis and Routledge Open articles and Taylor & Francis and Routledge Open Select articles posted to institutional or subject repositories or any other third-party website are without warranty from Taylor & Francis of any kind, either expressed or implied, including, but not limited to, warranties of merchantability, fitness for a particular purpose, or non-infringement. Any opinions and views expressed in this article are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor & Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content. This article may be used for research, teaching, and private study purposes. Terms & Conditions of access and use can be found at http://www.tandfonline.com/page/terms-and-conditions It is essential that you check the license status of any given Open and Open Select article to confirm conditions of access and use.
Editor's Corner
Editor's Corner
Human Vaccines & Immunotherapeutics 9:11, 2277–2278; November 2013; © 2013 Landes Bioscience
Letter from the Editor Ronald Ellis1,* and Eva M. Riedmann2 Senior Vice President R&D and Chief Technology Officer; NasVax, Ltd.; Ness Ziona, Israel; 2Acquisitions Editor; Landes Bioscience; Vienna, Austria
1
Dear Reader,
Downloaded by [Michigan State University] at 00:12 23 February 2015
In the current issue we are pleased to present a Review in the section HPV/Health Economics dealing with cost-effectiveness analyses of vaccinating males against HPV (Jiang, p. 2285). Four articles in the category Licensed Vaccines, look at genetic characteristics of Neisseria meningitides serogroup B strains carried by adolescents (Esposito, p. 2296), persistence of antibodies in adolescents after immunization with 4CMenB meningococcal serogroup B vaccine (Santolaya, p. 2304), safety and immunogenicity of Haemophilus influenza type b conjugate vaccines in Chinese infants (Shi, p. 2311), and vaccination for typhoid fever in Sub-Saharan Africa (Arya, p. 2316). Multiple papers fall into the category Novel Vaccines, including three studies on dengue vaccine development looking at the persistence of Th1/Tc1 responses after tetravalent dengue vaccination (Harenberg, p. 2317), immune responses in mice induced by vaccination with DENV-2 recombinant proteins (Garcia-Machorro, p. 2326), and immunogenicity of photo-inactivated dengue virus in mice (Raviprakash, p. 2336). Two papers deal with purification (Curti, p. 2342) as well as biophysical and formulation studies (Cheng, p. 2351) of the extracellular domain of the Schistosoma mansoni TSP-2 recombinant protein, a lead vaccine candidate antigen for human intestinal schistosomiasis. Anthrax vaccine development is the topic of two papers in this track: biophysical characterization and immunogenicity studies of the candidate anthrax toxin subunit vaccine dominant negative inhibitor (Iyer, p. 2362), and in vitro and in vivo activities of recombinant anthrax protective antigen co-expressed with thioredoxin in E. coli (Ma, p. 2371). Papers on a trivalent vaccine comprising H5N1/EV71/JEV antigens (Lin, p. 2378), a low-toxic site-directed mutant of Clostridium perfringens ε-toxin as a potential candidate vaccine against enterotoxemia (Li, p. 2386), and strategies for vaccine development against group A Streptococcus (Good, p. 2393) complete this section. Three papers related to Rotavirus include a regulatory agency inquiry into potential porcine circovirus type 1 in the human rotavirus vaccine Rotarix (Dubin, p. 2398), a study of rotavirus-specific antibodies in children with acute gastroenteritis and children vaccinated with an attenuated human rotavirus vaccine (Herrera, p. 2409), as well as a commentary on how to overcome perceptions of financial barriers to rotavirus vaccine introduction in Asia (Nelson, p. 2418). The section Immunotherapy features two papers on long-term survival and outcomes of patients given Mybacterium vaccae for metastatic malignant melanoma (Cananzi, p. 2427), and multi-therapeutic potential of autoantibodies induced by immune complexes trapped on follicular dendritic cells (El Shikh, p. 2434). A commentary on Immunotherapy/HIV discusses dendritic-cell-based therapeutic vaccines for HIV (Garcia, p. 2445). Two papers on Influenza deal with evaluation of seasonal influenza vaccine effectiveness (Falchi, p. 2453), and safety, immunogenicity and tolerability of three different influenza vaccines in older adults (Scheifele, p. 2460). The section on Hepatitis features a study on the immunogenicity and safety of hepatitis E vaccine in healthy hepatitis B surface antigen-positive adults (Wu, p. 2474), and a case report of acute hepatitis A in an elderly patient after care worker travel to high endemicity country (Aasheim, p. 2480). Finally, one paper on Vaccine Acceptance/HPV investigates social media microblogs as an HPV vaccination forum (Zhang, p. 2483), and one paper in the category Patents identifies factors that result in obviousness rulings for certain biotech patents (Lin, p. 2490). As always, our monthly News, Policy & Profiles (NP&P) section provides you with a selection of the latest news in the field of vaccines and immunotherapeutics. In our NP&P track we also regularly present companies and organizations related to vaccines and immunotherapy, and we are pleased to feature the Swiss biotech company VAXIMM in the current issue. VAXIMM develops active anti-angiogenic immunotherapies for cancer patients, and Drs Klaus Breiner, Executive Chairman, and Heinz Lubenau, General Manager of VAXIMM, have kindly agreed to answer our questions. If you would like to see your company/organization featured in *Correspondence to: Ronald Ellis; Email: [email protected] Submitted: 10/27/2013; Accepted: 10/27/2013 http://dx.doi.org/10.4161/hv.27083 www.landesbioscience.com
Human Vaccines & Immunotherapeutics 2277
Editor's Corner
Human Vaccines & Immunotherapeutics 9:11, 2278–2278; November 2013; © 2013 Landes Bioscience
a future issue of HV&I, simply contact Eva Riedmann ([email protected]). Furthermore, our NP&P section accepts commentaries on timely, interesting and controversial topics in the field of vaccines and/or immunotherapy. Your ideas for our NP&P track are always welcome. Finally, we want to draw your attention to several popular web site features, which are usuable on all electronic devices, such as mobile phones and tablets, an RSS feed to see the latest published papers, and a HV&I facebook account for daily updates.
Sincerely,
Downloaded by [Michigan State University] at 00:12 23 February 2015
Ronald Ellis, PhD Editor-in-Chief Eva M Riedmann, PhD Acquisitions Editor
2278
Human Vaccines & Immunotherapeutics
Volume 9 Issue 11
Human Vaccines & Immunotherapeutics Publication details, including instructions for authors and subscription information: http://www.tandfonline.com/loi/khvi20
Letter from the Editor a
Ronald Ellis & Eva M Riedmann a
b
Senior Vice President R&D and Chief Technology Officer; NasVax, Ltd.; Ness Ziona, Israel
b
Acquisitions Editor; Landes Bioscience; Vienna, Austria Published online: 05 Nov 2013.
To cite this article: Ronald Ellis & Eva M Riedmann (2013) Letter from the Editor, Human Vaccines & Immunotherapeutics, 9:11, 2277-2278, DOI: 10.4161/hv.27083 To link to this article: http://dx.doi.org/10.4161/hv.27083
PLEASE SCROLL DOWN FOR ARTICLE Taylor & Francis makes every effort to ensure the accuracy of all the information (the “Content”) contained in the publications on our platform. Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Versions of published Taylor & Francis and Routledge Open articles and Taylor & Francis and Routledge Open Select articles posted to institutional or subject repositories or any other third-party website are without warranty from Taylor & Francis of any kind, either expressed or implied, including, but not limited to, warranties of merchantability, fitness for a particular purpose, or non-infringement. Any opinions and views expressed in this article are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor & Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content. This article may be used for research, teaching, and private study purposes. Terms & Conditions of access and use can be found at http://www.tandfonline.com/page/terms-and-conditions It is essential that you check the license status of any given Open and Open Select article to confirm conditions of access and use.
Editor's Corner
Editor's Corner
Human Vaccines & Immunotherapeutics 9:11, 2277–2278; November 2013; © 2013 Landes Bioscience
Letter from the Editor Ronald Ellis1,* and Eva M. Riedmann2 Senior Vice President R&D and Chief Technology Officer; NasVax, Ltd.; Ness Ziona, Israel; 2Acquisitions Editor; Landes Bioscience; Vienna, Austria
1
Dear Reader,
Downloaded by [Michigan State University] at 00:12 23 February 2015
In the current issue we are pleased to present a Review in the section HPV/Health Economics dealing with cost-effectiveness analyses of vaccinating males against HPV (Jiang, p. 2285). Four articles in the category Licensed Vaccines, look at genetic characteristics of Neisseria meningitides serogroup B strains carried by adolescents (Esposito, p. 2296), persistence of antibodies in adolescents after immunization with 4CMenB meningococcal serogroup B vaccine (Santolaya, p. 2304), safety and immunogenicity of Haemophilus influenza type b conjugate vaccines in Chinese infants (Shi, p. 2311), and vaccination for typhoid fever in Sub-Saharan Africa (Arya, p. 2316). Multiple papers fall into the category Novel Vaccines, including three studies on dengue vaccine development looking at the persistence of Th1/Tc1 responses after tetravalent dengue vaccination (Harenberg, p. 2317), immune responses in mice induced by vaccination with DENV-2 recombinant proteins (Garcia-Machorro, p. 2326), and immunogenicity of photo-inactivated dengue virus in mice (Raviprakash, p. 2336). Two papers deal with purification (Curti, p. 2342) as well as biophysical and formulation studies (Cheng, p. 2351) of the extracellular domain of the Schistosoma mansoni TSP-2 recombinant protein, a lead vaccine candidate antigen for human intestinal schistosomiasis. Anthrax vaccine development is the topic of two papers in this track: biophysical characterization and immunogenicity studies of the candidate anthrax toxin subunit vaccine dominant negative inhibitor (Iyer, p. 2362), and in vitro and in vivo activities of recombinant anthrax protective antigen co-expressed with thioredoxin in E. coli (Ma, p. 2371). Papers on a trivalent vaccine comprising H5N1/EV71/JEV antigens (Lin, p. 2378), a low-toxic site-directed mutant of Clostridium perfringens ε-toxin as a potential candidate vaccine against enterotoxemia (Li, p. 2386), and strategies for vaccine development against group A Streptococcus (Good, p. 2393) complete this section. Three papers related to Rotavirus include a regulatory agency inquiry into potential porcine circovirus type 1 in the human rotavirus vaccine Rotarix (Dubin, p. 2398), a study of rotavirus-specific antibodies in children with acute gastroenteritis and children vaccinated with an attenuated human rotavirus vaccine (Herrera, p. 2409), as well as a commentary on how to overcome perceptions of financial barriers to rotavirus vaccine introduction in Asia (Nelson, p. 2418). The section Immunotherapy features two papers on long-term survival and outcomes of patients given Mybacterium vaccae for metastatic malignant melanoma (Cananzi, p. 2427), and multi-therapeutic potential of autoantibodies induced by immune complexes trapped on follicular dendritic cells (El Shikh, p. 2434). A commentary on Immunotherapy/HIV discusses dendritic-cell-based therapeutic vaccines for HIV (Garcia, p. 2445). Two papers on Influenza deal with evaluation of seasonal influenza vaccine effectiveness (Falchi, p. 2453), and safety, immunogenicity and tolerability of three different influenza vaccines in older adults (Scheifele, p. 2460). The section on Hepatitis features a study on the immunogenicity and safety of hepatitis E vaccine in healthy hepatitis B surface antigen-positive adults (Wu, p. 2474), and a case report of acute hepatitis A in an elderly patient after care worker travel to high endemicity country (Aasheim, p. 2480). Finally, one paper on Vaccine Acceptance/HPV investigates social media microblogs as an HPV vaccination forum (Zhang, p. 2483), and one paper in the category Patents identifies factors that result in obviousness rulings for certain biotech patents (Lin, p. 2490). As always, our monthly News, Policy & Profiles (NP&P) section provides you with a selection of the latest news in the field of vaccines and immunotherapeutics. In our NP&P track we also regularly present companies and organizations related to vaccines and immunotherapy, and we are pleased to feature the Swiss biotech company VAXIMM in the current issue. VAXIMM develops active anti-angiogenic immunotherapies for cancer patients, and Drs Klaus Breiner, Executive Chairman, and Heinz Lubenau, General Manager of VAXIMM, have kindly agreed to answer our questions. If you would like to see your company/organization featured in *Correspondence to: Ronald Ellis; Email: [email protected] Submitted: 10/27/2013; Accepted: 10/27/2013 http://dx.doi.org/10.4161/hv.27083 www.landesbioscience.com
Human Vaccines & Immunotherapeutics 2277
Editor's Corner
Human Vaccines & Immunotherapeutics 9:11, 2278–2278; November 2013; © 2013 Landes Bioscience
a future issue of HV&I, simply contact Eva Riedmann ([email protected]). Furthermore, our NP&P section accepts commentaries on timely, interesting and controversial topics in the field of vaccines and/or immunotherapy. Your ideas for our NP&P track are always welcome. Finally, we want to draw your attention to several popular web site features, which are usuable on all electronic devices, such as mobile phones and tablets, an RSS feed to see the latest published papers, and a HV&I facebook account for daily updates.
Sincerely,
Downloaded by [Michigan State University] at 00:12 23 February 2015
Ronald Ellis, PhD Editor-in-Chief Eva M Riedmann, PhD Acquisitions Editor
2278
Human Vaccines & Immunotherapeutics
Volume 9 Issue 11
